Deficiency in the NADPH oxidase 4 predisposes towards diet-induced obesity

International Journal of Obesity

Volumn 36, Issue 12, 2012, Pages 1503-1513

  Li, Y ^a,c   Mouche, S ^a   Sajic, T ^a   Veyrat Durebex, C ^a   Supale, R ^a   Pierroz, D ^a   Ferrari, S ^a   Negro, F ^b   Hasler, U ^a   Feraille, E ^a   Moll, S ^b   Meda, P ^a   Deffert, C ^b   Montet, X ^a   Krause, K H ^b   Szanto, I ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c BEIJING HOSPITAL   (China)

Author keywords

adipocyte differentiation; high fat diet; NOX4

Indexed keywords

FATTY ACID; GLYCOGEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; DISEASE SEVERITY; FAT INTAKE; GENE EXPRESSION; HISTOLOGY; HOMEOSTASIS; HYPOXIA; IN VIVO STUDY; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLISM; MOUSE; NONHUMAN; OBESITY; OXIDATION; PANCREAS ISLET; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; STEATOSIS; TISSUE DIFFERENTIATION; UPREGULATION; WEIGHT GAIN; WESTERN BLOTTING; WILD TYPE;

ADIPOCYTES; ADIPOSE TISSUE; ADIPOSITY; ANIMALS; BLOTTING, WESTERN; DIET, HIGH-FAT; FATTY ACIDS; FATTY LIVER; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; MICE; NADPH OXIDASE; OBESITY; REAL-TIME POLYMERASE CHAIN REACTION; UP-REGULATION; WEIGHT GAIN;

MUS;

EID: 84870994653     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2011.279     Document Type: Article

References (54)

1. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007; 87: 245-313.
2. Geiszt M, Kopp JB, Varnai P, Leto TL. Identification of renox, an NAD(P)H oxidase in kidney. Proc Natl Acad Sci USA 2000; 97: 8010-8014.
3. Shiose A, Kuroda J, Tsuruya K, Hirai M, Hirakata H, Naito S, et al. A novel superoxide-producing NAD(P)H oxidase in kidney. J Biol Chem 2001; 276: 1417-1423.
4. Serrander L, Cartier L, Bedard K, Banfi B, Lardy B, Plastre O, et al. NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. Biochem J 2007; 406: 105-114.
5. Meng D, Lv DD, Fang J. Insulin-like growth factor-I induces reactive oxygen species production and cell migration through Nox4 and Rac1 in vascular smooth muscle cells. Cardiovasc Res 2008; 80: 299-308.
6. Mahadev K, Motoshima H, Wu X, Ruddy JM, Arnold RS, Cheng G, et al. The NAD(P)H oxidase homolog Nox4 modulates insulin-stimulated generation of H2O2 and plays an integral role in insulin signal transduction. Mol Cell Biol 2004; 24: 1844-1854.
7. Loh K, Deng H, Fukushima A, Cai X, Boivin B, Galic S, et al. Reactive oxygen species enhance insulin sensitivity. Cell Metab 2009; 10: 260-272.
8. Entingh AJ, Taniguchi CM, Kahn CR. Bi-directional regulation of brown fat adipogenesis by the insulin receptor. J Biol Chem 2003; 278: 33377-33383.
9. Bluher M, Michael MD, Peroni OD, Ueki K, Carter N, Kahn BB, et al. Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev Cell 2002; 3: 25-38.
10. Schroder K, Wandzioch K, Helmcke I, Brandes RP. Nox4 acts as a switch between differentiation and proliferation in preadipocytes. Arterioscler Thromb Vasc Biol 2009; 29: 239-245.
11. Mouche S, Mkaddem SB, Wang W, Katic M, Tseng YH, Carnesecchi S, et al. Reduced expression of the NADPH oxidase NOX4 is a hallmarkofadipocyte differentiation. Biochim Biophys Acta 2007; 1773: 1015-1027.
12. Goossens GH. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav 2008; 94: 206-218.
13. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. JClin Invest 2004; 114: 1752-1761.
14. Park HS, Jin DK, Shin SM, Jang MK, Longo N, Park JW, et al. Impaired generation of reactive oxygen species in leprechaunism through downregulation of Nox4. Diabetes 2005; 54: 3175-3181.
15. Carnesecchi S, Deffert C, Donati Y, Basset O, Hinz B, Preynat-Seauve O, et al. A key rolefor NOX4 in epithelial cell death during developmentoflung fibrosis. Antioxid Redox Signal 15: 607-619.
16. Somm E, Henrichot E, Pernin A, Juge-Aubry CE, Muzzin P, Dayer JM, et al. Decreased fat mass in interleukin-1 receptor antagonist-deficient mice: impact on adipogenesis, food intake, and energy expenditure. Diabetes 2005; 54: 3503-3509.
17. Veyrat-Durebex C, Montet X, Vinciguerra M, Gjinovci A, Meda P, Foti M, et al. The Lou/C rat: a model of spontaneous food restriction associated with improved insulin sensitivity and decreased lipid storage in adipose tissue. Am J Physiol Endocrinol Metab 2009; 296: E1120-E1132.
18. Baran K, Preston E, Wilks D, Cooney GJ, Kraegen EW, Sainsbury A. Chronic central melanocortin-4 receptor antagonism and central neuropeptide-Y infusion in rats produce increased adiposity by divergent pathways. Diabetes 2002; 51: 152-158.
19. Crosson SM, Khan A, Printen J, Pessin JE, Saltiel AR. PTG gene deletion causes impaired glycogen synthesis and developmental insulin resistance. J Clin Invest 2003; 111: 1423-1432.
20. Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 2007; 92: 1023-1033.
21. Johnson JA, Trasino SE, Ferrante Jr AW, Vasselli Jr. Prolonged decrease of adipocyte size after rosiglitazone treatment in high-and low-fat-fed rats. Obesity (Silver Spring) 2007; 15: 2653-2663.
22. Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, Segawa K, et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 2007; 56: 901-911.
23. Ye J, Gao Z, Yin J, He Q. Hypoxia is a potential riskfactor for chronic inflammation and adiponectin reduction in adipose tissueofob/ob and dietary obese mice. Am J Physiol Endocrinol Metab 2007; 293: E1118-E1128.
24. Wood IS, de Heredia FP, Wang B, Trayhurn P. Cellular hypoxia and adipose tissue dysfunction in obesity. Proc Nutr Soc 2009; 68: 370-377.
25. Lee MJ, Wu Y, Fried SK. Adipose tissue remodeling in pathophysiology ofobesity. Curr Opin Clin Nutr Metab Care 2010; 13: 371-376.
26. Alkhouri N, Gornicka A, Berk MP, Thapaliya S, Dixon LJ, Kashyap S, et al. Adipocyte apoptosis, a link between obesity, insulin resistance, and hepatic steatosis. J Biol Chem 2010; 285: 3428-3438.
27. Anghel SI, Wahli W. Fat poetry: a kingdom for PPAR gamma. Cell Res 2007; 17: 486-511.
28. Armoni M, Kritz N, Harel C, Bar-Yoseph F, Chen H, Quon MJ, et al. Peroxisome proliferator-activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect. J Biol Chem 2003; 278: 30614-30623.
29. Stephens JM, Pekala PH. Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. J Biol Chem 1991; 266: 21839-21845.
30. Kloting N, Berthold S, Kovacs P, Schon MR, Fasshauer M, Ruschke K, et al. MicroRNA expression in human omental and subcutaneous adipose tissue. PLoS One 2009; 4: e 4699.
31. Takanabe R, Ono K, Abe Y, Takaya T, Horie T, Wada H, et al. Up-regulated expression of microRNA-143 in association with obesity in adipose tissue of mice fed high-fat diet. Biochem Biophys Res Commun 2008; 376: 728-732.
32. Kim YJ, Hwang SJ, Bae YC, Jung JS. MiR-21 regulates adipogenic differentiation through the modulation of TGF-beta signaling in mesenchymal stem cells derived from human adipose tissue. Stem Cells 2009; 27: 3093-3102.
33. Sharma MR, Polavarapu R, Roseman D, Patel V, Eaton E, Kishor PB, et al. Transcriptional networks in a rat model for nonalcoholic fatty liver disease: a microarray analysis. Exp Mol Pathol 2006; 81: 202-210.
34. Reddy JK, Rao MS. Lipid metabolism and liver inflammation. I. Hepatic fatty acid uptake: possible role in steatosis. Am J Physiol Gastrointest Liver Physiol 2006; 290: G852-G858.
35. Uemura M, Swenson ES, Gaca MD, Giordano FJ, Reiss M, Wells RG. Smad2 and Smad3 play different roles in rat hepatic stellate cell function and alpha-smooth muscle actin organization. Mol Biol Cell 2005; 16: 4214-4224.
36. Brenner DA. Molecular pathogenesis ofliverfibrosis. Trans Am Clin Climatol Assoc 2009; 120: 361-368.
37. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009; 58: 250-259.
38. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, et al. FGF-21 as a novel metabolic regulator.JClin Invest 2005; 115: 1627-1635.
39. Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007; 148: 774-781.
40. Dushay J, Chui PC, Gopalakrishnan GS, Varela-Rey M, Crawley M, Fisher FM, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010; 139: 456-463.
41. Horvath TL, Andrews ZB, Diano S. Fuel utilization by hypothalamic neurons: roles for ROS. Trends Endocrinol Metab 2009; 20: 78-87.
42. Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 2008; 118: 2992-3002.
43. Trayhurn P, Wang B, Wood IS. Hypoxia and the endocrine and signalling role of white adipose tissue. Arch Physiol Biochem 2008; 114: 267-276.
44. Lee YH, Nair S, Rousseau E, Allison DB, Page GP, Tataranni PA, et al. Microarray profiling of isolated abdominal subcutaneous adipocytes from obese vs non-obese Pima Indians: increased expression of inflammation-related genes. Diabetologia 2005; 48: 1776-1783.
45. Bradbury MW. Lipid metabolism and liver inflammation. I. Hepatic fatty acid uptake: possible role in steatosis. Am J Physiol Gastrointest Liver Physiol 2006; 290: G194-G198.
46. Hijona E, Hijona L, Arenas JI, Bujanda L. Inflammatory mediators of hepatic steatosis. Mediators Inflamm 2010; 2010: 837419.
47. Carmona-Cuenca I, Roncero C, Sancho P, Caja L, Fausto N, Fernandez M, et al. Upregulation of the NADPH oxidase NOX4 by TGF-beta in hepatocytes is required for its pro-apoptotic activity. J Hepatol 2008; 49: 965-976.
48. Hecker L, Vittal R, Jones T, Jagirdar R, Luckhardt TR, Horowitz JC, et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med 2009; 15: 1077-1081.
49. Ghouri N, Preiss D, Sattar N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology 2010; 52: 1156-1161.
50. Dunn W, Xu R, Wingard DL, Rogers C, Angulo P, Younossi ZM, et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 2008; 103: 2263-2271.
51. McKimmie RL, Daniel KR, Carr JJ, Bowden DW, Freedman BI, Register TC, et al. Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the Diabetes Heart Study. Am J Gastroenterol 2008; 103: 3029-3035.
52. Rivera J, Sobey CG, Walduck AK, Drummond GR. Nox isoforms in vascular pathophysiology: insights from transgenic and knockout mouse models. Redox Rep 2010; 15: 50-63.
53. Nabeebaccus A, Zhang M, Shah AM. NADPH oxidases and cardiac remodelling. Heart Fail Rev 2011; 16: 5-12.
54. van Tilburg JH, Sandkuijl LA, Strengman E, Pearson PL, van Haeften TW, Wijmenga C. Variance-component analysis of obesity in type 2 diabetes confirms loci on chromosomes 1q and 11q. Obes Res 2003; 11: 1290-1294.